The Full Wiki

List of monoclonal antibodies: Wikis

Advertisements
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies which are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.

The abbreviations in the column Type are as follows:

This list includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage.

Name Trade name Type Source Target Use
3F8  ? mouse GD2 neuroblastoma
Abagovomab[1] mab mouse CA-125 (imitation) ovarian cancer
Abciximab ReoPro Fab chimeric (CD41 (integrin alpha-IIb) platelet aggregation inhibitor
Adalimumab Humira mab human TNF-α rheumatoid arthritis etc.
Adecatumumab[2] mab human EpCAM prostate and breast cancer
Afelimomab F(ab')2 mouse TNF-α sepsis
Afutuzumab[3] mab humanized CD20 lymphoma
Alacizumab pegol[4] F(ab')2 humanized VEGFR2 cancer
ALD518[5]  ? humanized IL-6 rheumatoid arthritis
Alemtuzumab[6] Campath, MabCampath mab humanized CD52 CLL, CTCL
Altumomab pentetate Hybri-ceaker mab mouse CEA colorectal cancer (diagnosis)
Anatumomab mafenatox Fab mouse glycoprotein 72 non-small cell lung carcinoma
Anrukinzumab[4] (= IMA-638)[7] mab humanized IL-13  ?
Apolizumab[8] mab humanized HLA-DR ? hematological cancers
Arcitumomab CEA-Scan Fab' mouse CEA gastrointestinal cancers (diagnosis)
Aselizumab[9] mab humanized L-selectin (CD62L) severely injured patients
Atlizumab (= tocilizumab) Actemra, RoActemra mab humanized IL-6 receptor rheumatoid arthritis
Atorolimumab mab human Rhesus factor hemolytic disease of the newborn[citation needed]
Bapineuzumab[10] mab humanized beta amyloid Alzheimer's disease
Basiliximab Simulect mab chimeric CD25 (α chain of IL-2 receptor) prevention of organ transplant rejections
Bavituximab[1] mab chimeric phosphatidylserine cancer, viral infections
Bectumomab LymphoScan Fab' mouse CD22 non-Hodgkin's lymphoma (detection)
Belimumab Benlysta, LymphoStat-B mab human BAFF non-Hodgkin lymphoma etc.
Bertilimumab[9] mab human CCL11 (eotaxin-1) severe allergic disorders
Besilesomab[11] Scintimun mab mouse CEA-related antigen inflammatory lesions and metastases (detection)
Bevacizumab[6] Avastin mab humanized VEGF-A metastatic cancer
Biciromab FibriScint Fab' mouse fibrin II, beta chain thromboembolism (diagnosis)
Bivatuzumab mertansine mab humanized CD44 v6 squamous cell carcinoma
Blinatumomab BiTE mouse CD19 cancer
Brentuximab vedotin[12] mab chimeric CD30 (TNFRSF8) hematologic cancers
Briakinumab[13] mab human IL-12, IL-23 psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Canakinumab[14] Ilaris mab human IL-1? rheumatoid arthritis
Cantuzumab mertansine mab humanized mucin CanAg colorectal cancer etc.
Capromab pendetide Prostascint mab mouse prostatic carcinoma cells prostate cancer (detection)
Catumaxomab[10] Removab 3funct rat/mouse hybrid EpCAM, CD3 ovarian cancer, malignant ascites, gastric cancer
Cedelizumab mab humanized CD4 prevention of organ transplant rejections, treatment of autoimmune diseases
Certolizumab pegol[2] Cimzia Fab' humanized TNF-α Crohn's disease
Cetuximab Erbitux mab chimeric EGFR metastatic colorectal cancer and head and neck cancer
Citatuzumab bogatox[3] Fab humanized EpCAM ovarian cancer and other solid tumors
Cixutumumab mab human IGF-1 receptor solid tumors
Clenoliximab mab chimeric CD4 rheumatoid arthritis
Clivatuzumab tetraxetan[15] mab humanized MUC1 pancreatic cancer
Conatumumab[3] mab human TRAIL-R2 cancer
Dacetuzumab[4] mab humanized CD40 hematologic cancers
Daclizumab Zenapax mab humanized CD25 (α chain of IL-2 receptor) prevention of organ transplant rejections
Daratumumab[16] mab human CD38 (cyclic ADP ribose hydrolase)  ?
Denosumab[17] Prolia mab human RANKL osteoporosis, bone metastases etc.
Detumomab mab mouse B-lymphoma cell lymphoma
Dorlimomab aritox[18] F(ab')2 mouse  ?  ?
Dorlixizumab  ? chimeric/humanized  ?  ?
Ecromeximab[8] mab chimeric GD3 ganglioside malignant melanoma
Eculizumab[8] Soliris mab humanized C5 paroxysmal nocturnal hemoglobinuria
Edobacomab mab mouse endotoxin sepsis caused by Gram-negative bacteria
Edrecolomab Panorex mab mouse EpCAM colorectal carcinoma
Efalizumab[19] Raptiva mab humanized CD11a psoriasis (blocks T-cell migration)
Efungumab[1] Mycograb scFv human Hsp90 invasive Candida infection
Elotuzumab mab humanized SLAMF7 multiple myeloma
Elsilimomab mab mouse IL-6  ?
Enlimomab pegol[20] mab mouse ICAM-1 (CD54)  ?
Epitumomab cituxetan[21] mab mouse episialin  ?
Epratuzumab mab humanized CD22 cancer, SLE
Erlizumab[22] F(ab')2 humanized ITGB2 (CD18) heart attack, stroke, traumatic shock
Ertumaxomab[10] Rexomun 3funct rat/mouse hybrid HER2/neu, CD3 breast cancer etc.
Etaracizumab Abegrin mab humanized integrin αvβ3 melanoma, prostate cancer, ovarian cancer etc.
Exbivirumab[23] mab human hepatitis B surface antigen hepatitis B
Fanolesomab[24] NeutroSpec mab mouse CD15 appendicitis (diagnosis)
Faralimomab mab mouse interferon receptor  ?
Farletuzumab mab humanized folate receptor 1 ovarian cancer
Felvizumab mab humanized respiratory syncytial virus respiratory syncytial virus infection
Fezakinumab[25][26][27] mab human IL-22 rheumatoid arthritis, psoriasis
Figitumumab mab human IGF-1 receptor adrenocortical carcinoma, non-small cell lung carcinoma etc.
Fontolizumab[8] HuZAF mab humanized IFN-γ Crohn's disease etc.
Foravirumab[3] mab human rabies virus glycoprotein rabies (prophylaxis)
Fresolimumab[28] mab human TGF-β idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Galiximab mab chimeric CD80 B-cell lymphoma
Gantenerumab[14] mab human beta amyloid Alzheimer's disease
Gavilimomab[22] mab mouse CD147 (basigin) graft versus host disease
Gemtuzumab ozogamicin Mylotarg mab humanized CD33 acute myelogenous leukemia
Girentuximab[16] mab chimeric carbonic anhydrase 9  ?
Golimumab[23] Simponi mab human TNF-α rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab  ? chimeric CD23 (IgE receptor) allergic asthma
Ibalizumab[14] mab humanized CD4 HIV infection
Ibritumomab tiuxetan Zevalin  ? mouse CD20 non-Hodgkin's lymphoma
Igovomab Indimacis-125 F(ab')2 mouse CA-125 ovarian cancer (diagnosis)
Imciromab Myoscint  ? mouse cardiac myosin cardiac imaging
Infliximab Remicade mab chimeric TNF-α rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[29][30][31] mab human CD51 solid tumors (prostate cancer, melanoma)
Inolimomab  ? mouse CD25 (α chain of IL-2 receptor) graft versus host disease
Inotuzumab ozogamicin[11] mab humanized CD22 cancer
Ipilimumab[17] mab human CD152 melanoma
Iratumumab[17] mab human CD30 (TNFRSF8) Hodgkin's lymphoma
Keliximab  ? chimeric CD4 chronic asthma
Labetuzumab[19] CEA-Cide mab humanized CEA colorectal cancer
Lebrikizumab[32] mab humanized IL-13 asthma
Lemalesomab[22] mab mouse NCA-90 (granulocyte antigen) diagnostic agent
Lerdelimumab[6] mab human TGF beta 2 reduction of scarring after glaucoma surgery
Lexatumumab[1] mab human TRAIL-R2 cancer
Libivirumab[23] mab human hepatitis B surface antigen hepatitis B
Lintuzumab  ? humanized CD33 cancer
Lucatumumab[4] mab human CD40 multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lumiliximab[2] mab chimeric CD23 (IgE receptor) chronic lymphocytic leukemia
Mapatumumab[10] mab human TRAIL-R1 cancer
Maslimomab  ? mouse T-cell receptor  ?
Matuzumab[9] mab humanized EGFR colorectal, lung and stomach cancer
Mepolizumab Bosatria  ? humanized IL-5 asthma and white blood cell diseases
Metelimumab[24] mab human TGF beta 1 systemic scleroderma
Milatuzumab[4] mab humanized CD74 multiple myeloma and other hematological malignancies
Minretumomab  ? mouse glycoprotein 72  ?
Mitumomab  ? mouse GD3 ganglioside small cell lung carcinoma
Morolimumab  ? human Rhesus factor  ?
Motavizumab[1] Numax mab humanized respiratory syncytial virus respiratory syncytial virus (prevention)
Muromonab-CD3 Orthoclone OKT3  ? mouse CD3 prevention of organ transplant rejections
Nacolomab tafenatox  ? mouse C242 antigen colorectal cancer
Naptumomab estafenatox[33] Fab mouse 5T4 non-small cell lung carcinoma, renal cell carcinoma
Natalizumab Tysabri  ? humanized integrin α4 multiple sclerosis, Crohn's disease
Nebacumab  ? human endotoxin sepsis
Necitumumab[34] mab human EGFR non-small cell lung carcinoma
Nerelimomab  ? mouse TNF-α  ?
Nimotuzumab[17][35] Theracim, Theraloc mab humanized EGFR squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nofetumomab merpentan Verluma  ? mouse  ? cancer (diagnosis)
Ocrelizumab[17] mab humanized CD20 rheumatoid arthritis, lupus erythematosus etc.
Odulimomab  ? mouse LFA-1 prevention of organ transplant rejections, immunological diseases
Ofatumumab[10] Arzerra mab human CD20 chronic lymphocytic leukemia etc.
Omalizumab[22] Xolair mab humanized IgE allergic asthma
Oportuzumab monatox[34] scFv humanized EpCAM cancer
Oregovomab[24] OvaRex mab mouse CA-125 ovarian cancer
Otelixizumab[4] mab chimeric/humanized CD3 diabetes mellitus type 1
Pagibaximab[10] mab chimeric lipoteichoic acid sepsis (Staphylococcus)
Palivizumab Synagis, Abbosynagis  ? humanized respiratory syncytial virus respiratory syncytial virus (prevention)
Panitumumab[23] Vectibix mab human EGFR colorectal cancer
Panobacumab[34] mab human Pseudomonas aeruginosa Pseudomonas aeruginosa infection
Pascolizumab[8] mab humanized IL-4 asthma
Pemtumomab Theragyn  ? mouse MUC1 cancer
Pertuzumab Omnitarg mab humanized HER2/neu cancer
Pexelizumab[19]  ? humanized C5 reduction of side effects of cardiac surgery
Pintumomab  ? mouse adenocarcinoma antigen adenocarcinoma (imaging)
Priliximab  ? chimeric CD4 Crohn's disease, multiple sclerosis
Pritumumab mab human vimentin brain cancer
PRO 140  ? humanized CCR5 HIV infection
Rafivirumab[3] mab human rabies virus glycoprotein rabies (prophylaxis)
Ramucirumab mab human VEGFR2 solid tumors
Ranibizumab[2] Lucentis Fab humanized VEGF-A macular degeneration (wet form)
Raxibacumab[11] mab human anthrax toxin, protective antigen anthrax (prophylaxis and treatment)
Regavirumab  ? human cytomegalovirus glycoprotein B cytomegalovirus infection
Reslizumab[19] mab humanized IL-5 inflammations of the airways, skin and gastrointestinal tract
Rilotumumab[36] mab human HGF solid tumors
Rituximab MabThera, Rituxan mab chimeric CD20 lymphomas, leukemias, some autoimmune disorders
Robatumumab mab human IGF-1 receptor cancer
Rontalizumab[37] mab humanized IFN-α systemic lupus erythematosus
Rovelizumab LeukArrest  ? humanized CD11, CD18 haemorrhagic shock etc.
Ruplizumab[6] Antova mab humanized CD154 (CD40L) rheumatic diseases
Satumomab  ? mouse glycoprotein 72 cancer (diagnosis)
Sevirumab  ? human cytomegalovirus cytomegalovirus infection
Sibrotuzumab  ? humanized FAP cancer
Sifalimumab[38] mab humanized IFN-α SLE, dermatomyositis, polymyositis
Siltuximab mab chimeric IL-6  ?
Siplizumab[8] mab humanized CD2 psoriasis, graft-versus-host disease (prevention)
Solanezumab[34] mab humanized beta amyloid Alzheimer's disease
Sonepcizumab[39]  ? humanized sphingosine-1-phosphate choroidal and retinal neovascularization
Sontuzumab[35]  ? humanized episialin  ?
Stamulumab[17][35] mab human myostatin muscular dystrophy
Sulesomab LeukoScan  ? mouse NCA-90 (granulocyte antigen) osteomyelitis (imaging)
Tacatuzumab tetraxetan AFP-Cide mab humanized alpha-fetoprotein cancer
Tadocizumab[35] Fab humanized integrin αIIbβ3 percutaneous coronary intervention
Talizumab mab humanized IgE allergic reaction
Tanezumab[3] mab humanized NGF pain
Taplitumomab paptox[22] mab mouse CD19 cancer[citation needed]
Tefibazumab[11] Aurexis mab humanized clumping factor A Staphylococcus aureus infection
Telimomab aritox Fab mouse  ?  ?
Tenatumomab[4] mab mouse tenascin C cancer
Teneliximab[8] mab chimeric CD40  ?
Teplizumab[14] mab humanized CD3 diabetes mellitus type 1
TGN1412  ? humanized CD28 chronic lymphocytic leukemia, rheumatoid arthritis
Ticilimumab (= tremelimumab) mab human CTLA-4 cancer
Tigatuzumab[4] mab humanized TRAIL-R2 cancer
TNX-650  ? humanized IL-13 Hodgkin's lymphoma
Tocilizumab[2] (= atlizumab) Actemra, RoActemra mab humanized IL-6 receptor rheumatoid arthritis
Toralizumab[8] mab humanized CD154 (CD40L) rheumatoid arthritis, lupus nephritis etc.
Tositumomab Bexxar  ? mouse CD20 follicular lymphoma
Trastuzumab Herceptin  ? humanized HER2/neu breast cancer
Tremelimumab mab human CTLA-4 cancer
Tucotuzumab celmoleukin[17][35] mab humanized EpCAM cancer
Tuvirumab  ? human hepatitis B virus chronic hepatitis B
Urtoxazumab[2]  ? humanized Escherichia coli diarrhoea caused by E. coli
Ustekinumab[3] Stelara mab human IL-12, IL-23 multiple sclerosis, psoriasis, psoriatic arthritis
Vapaliximab[8] mab chimeric AOC3 (VAP-1)  ?
Vedolizumab mab humanized integrin α4β7 Crohn's disease, ulcerative colitis
Veltuzumab[4] mab humanized CD20 non-Hodgkin's lymphoma
Vepalimomab  ? mouse AOC3 (VAP-1) inflammation
Visilizumab[22] Nuvion mab humanized CD3 Crohn's disease, ulcerative colitis
Volociximab[10] mab chimeric integrin α5β1 solid tumors
Votumumab HumaSPECT  ? human carcinoma-associated antigen colorectal tumors
Zalutumumab[10] HuMax-EGFr mab human EGFR squamous cell carcinoma of the head and neck
Zanolimumab[2] HuMax-CD4 mab human CD4 rheumatoid arthritis, psoriasis, T-cell lymphoma
Ziralimumab[22] mab human CD147 (basigin)  ?
Zolimomab aritox  ? mouse CD5 systemic lupus erythematosus, graft-versus-host disease

References

  1. ^ a b c d e World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information 20 (2). http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf. 
  2. ^ a b c d e f g World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90" (PDF). WHO Drug Information 18 (1). http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf. 
  3. ^ a b c d e f g World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99" (PDF). WHO Drug Information 22 (2). http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf. 
  4. ^ a b c d e f g h i World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information 21 (4). http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf. 
  5. ^ "BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009. http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire. 
  6. ^ a b c d World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information 14 (2). http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf. 
  7. ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. http://www.wyeth.com/research/projects. Retrieved November 19, 2008. 
  8. ^ a b c d e f g h i World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87" (PDF). WHO Drug Information 16 (2). http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf. 
  9. ^ a b c World Health Organization (2003). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88" (PDF). WHO Drug Information 17 (1). http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf. 
  10. ^ a b c d e f g h World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93" (PDF). WHO Drug Information 19 (2). http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf. 
  11. ^ a b c d World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92" (PDF). WHO Drug Information 18 (4). http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf. 
  12. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf. 
  13. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf. 
  14. ^ a b c d World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97" (PDF). WHO Drug Information 21 (2). http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf. 
  15. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf. 
  16. ^ a b World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101" (PDF). WHO Drug Information 23 (2). http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf. 
  17. ^ a b c d e f g World Health Organization (2005). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94" (PDF). WHO Drug Information 19 (4). http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf. 
  18. ^ World Health Organization (1991). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66" (PDF). WHO Drug Information 5 (4). http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf. 
  19. ^ a b c d World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85" (PDF). WHO Drug Information 15 (2). http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf. 
  20. ^ World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information 11 (2). http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf. 
  21. ^ World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51" (PDF). WHO Drug Information 18 (1). http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf. 
  22. ^ a b c d e f g World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84" (PDF). WHO Drug Information 14 (4). http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf. 
  23. ^ a b c d World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91" (PDF). WHO Drug Information 18 (2). http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf. 
  24. ^ a b c World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86" (PDF). WHO Drug Information 16 (12). http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf. 
  25. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf. 
  26. ^ ClinicalTrials.gov NCT00883896 Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis
  27. ^ ClinicalTrials.gov NCT00563524 Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis
  28. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf. 
  29. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf. 
  30. ^ ClinicalTrials.gov NCT00537381 A Study of the Safety and Effectiveness of CNTO 95 in Patients Wih Metastatic Hormone Refractory Prostate Cancer
  31. ^ ClinicalTrials.gov NCT00246012 A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma
  32. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf. 
  33. ^ World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96" (PDF). WHO Drug Information 20 (4). http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf. 
  34. ^ a b c d World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy)" (PDF). WHO Drug Information. http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf. 
  35. ^ a b c d e World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56" (PDF). WHO Drug Information 20 (3). http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf. 
  36. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf. 
  37. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf. 
  38. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf. 
  39. ^ Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization". Journal of Cellular Physiology 218 (1): 192. doi:10.1002/jcp.21588. PMID 18781584.  edit
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message